Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

IODIXANOL CRS (40 MG)

IODIXANOL CRS (40 MG)

92339-11-2

DISCOVER
SPIRONOLACTONE FOR SYSTEM SUITABILITY CRS (2.06 MG)

SPIRONOLACTONE FOR SYSTEM SUITABILITY CRS (2.06 MG)

52-01-7

DISCOVER
NORTRIPTYLINE FOR SYSTEM SUITABILITY CRS (20 MG)

NORTRIPTYLINE FOR SYSTEM SUITABILITY CRS (20 MG)

894-71-3

DISCOVER
IOPENTOL CRS (10 MG)

IOPENTOL CRS (10 MG)

89797-00-2

DISCOVER
CHLORAMBUCIL FOR SYSTEM SUITABILITY CRS (10 MG)

CHLORAMBUCIL FOR SYSTEM SUITABILITY CRS (10 MG)

305-03-3

DISCOVER
CHLORAMBUCIL WITH IMPURITY G CRS (10 MG)

CHLORAMBUCIL WITH IMPURITY G CRS (10 MG)

305-03-3

DISCOVER
SODIUM CROMOGLICATE FOR SYSTEM SUITABILITY CRS (20 MG)

SODIUM CROMOGLICATE FOR SYSTEM SUITABILITY CRS (20 MG)

15826-37-6

DISCOVER
NORFLOXACIN FOR PEAK IDENTIFICATION CRS (15 MG)

NORFLOXACIN FOR PEAK IDENTIFICATION CRS (15 MG)

70458-96-7

DISCOVER
RIZATRIPTAN BENZOATE CRS (200MG)

RIZATRIPTAN BENZOATE CRS (200MG)

145202-66-0

DISCOVER
RIZATRIPTAN FOR SYSTEM SUITABILITY CRS (15 MG)

RIZATRIPTAN FOR SYSTEM SUITABILITY CRS (15 MG)

145202-66-0

DISCOVER
BUTYL METHANESULFONATE CRS (30 µL)

BUTYL METHANESULFONATE CRS (30 µL)

1912-32-9

DISCOVER
CEFPODOXIME PROXETIL CRS (80 MG)

CEFPODOXIME PROXETIL CRS (80 MG)

87239-81-4

DISCOVER